Last reviewed · How we verify

NCT04939753

Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis

Completed Last updated 27 April 2023
What this trial tests

trial testing Sevoflurane in Nephrogenic Diabetes Insipidus in 1,000 participants. Completed in 1 April 2023.

Timeline
26 May 2021
Primary endpoint
1 April 2023
1 April 2023

Quick facts

Lead sponsorUniversitair Ziekenhuis Brussel
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,000
Start date26 May 2021
Primary completion1 April 2023
Estimated completion1 April 2023
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Universitair Ziekenhuis Brussel — full company profile →

Who can join

18 and older, any sex, with Nephrogenic Diabetes Insipidus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to retrospectively explore the electronic medical records of all patients who were admitted to the Intensive Care Unit (ICU) of the UZ Brussels in the last 10 years (March 1st 2011- March 1st 2021) and who received prolonged sedation (\>24h) with sevoflurane.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sevoflurane

Trials testing the same drug.

Other recruiting trials for Nephrogenic Diabetes Insipidus

Currently open trials in the same condition.

Other Universitair Ziekenhuis Brussel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04939753.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing